What Has Been the Growth of the Major Depressive Disorder Market So Far?
The major depressive disorder market has seen considerable growth due to a variety of factors.
• The market for major depressive disorder has seen a consistent increase in size over recent time. It is projected to rise from $6.12 billion in 2024 to $6.28 billion in 2025, indicating a compound annual growth rate (CAGR) of 2.6%.
This growth during the historic period can be contributed to the advancements in pharmaceuticals, increased mental health consciousness, psychological treatments, and public health programs.
How Will the Major Depressive Disorder Market?
The major depressive disorder market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, we anticipate stable expansion in the market size for major depressive disorder. It's projected to escalate to $7.13 billion by 2029, with a compound annual growth rate (CAGR) of 3.2%.
Factors contributing to the growth throughout the forecast duration include advancements in precision medicine, telepsychiatry and teletherapy, innovative treatment methods, and the worldwide spread of mental health services. Significant trends expected within this period encompass early intervention, peer backing and digital communities, integrated approaches, as well as tactics for resilience and coping.
Which Factors Are Boosting Growth In The Major Depressive Disorder Market?
The major depressive disorder market is predicted to expand due to an increase in substance abuse and alcoholism cases. Substance and alcohol misuse refer to harmful and excessive usage patterns that can result in undesirable physical, psychological, and social outcomes. Substance and alcohol misuse often coincide with major depressive disorder, exacerbating the risk of bodily and mental harm. For example, a study in July 2024 by the Substance Abuse and Mental Health Services Administration (a division of US Health and Human Services) revealed that 3.1% of people (about 8.9 million) misused opioids in 2023, and 21.8% of individuals aged 12 or above consumed marijuana, the most commonly used illegal drug. Furthermore, 9.4% of individuals aged 12 or more vaped nicotine in the previous month, a growth from 8.3% in 2022. Hence, the increasing instances of substance and alcohol misuse are contributing to the expansion of the major depressive disorder market.
Major Depressive Disorder Market Driver: Rise in Anxiety Cases Fuels Market Expansion
What Key Areas Define The Segmentation Of The Global Major Depressive Disorder Market?
The major depressive disorder market covered in this report is segmented –
1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments
2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-
5), Other Diagnosis
3) By End-User: Clinics, Hospitals, Other End-Users
Subsegments:
1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy
2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT
4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)
5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)
Pre-Book The Major Depressive Disorder Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Major Depressive Disorder Market?
Key businesses in the major depressive disorder industry are concentrated on creating novel products and obtaining necessary approvals to establish a competitive edge. The number of approved drugs for treating major depressive disorder, such as VRAYLAR (cariprazine), is on the rise due to demand for safer and more effective therapies. For example, in December 2022, the US-based pharmaceutical corporation, AbbVie Inc., secured approval from the US federal agency, the Food and Drug Administration (FDA), for VRAYLAR (cariprazine) to serve as a supplementary therapy to antidepressants for adults with major depressive disorder (MDD). VRAYLAR is a groundbreaking atypical antipsychotic medication that regulates dopamine and serotonin levels in the brain and stands as the first atypical antipsychotic authorized as a supplementary treatment for major depressive disorder. Moreover, it comes in the form of a capsule and is ingested once daily.
Who Are the Key Players In The Major Depressive Disorder Market?
Major companies operating in the major depressive disorder market are:
• Pfizer Inc.
• Janssen Research And Development LLC
• Merck and Co. Inc.
• Novartis AG
• Sanofi-Aventis US LLC
• Bristol Myers Squibb Co.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Biogen Inc.
• Otsuka Pharmaceuticals Co.Ltd.
• Forest Laboratories Inc.
• H. Lundbeck A/S
• Richter Gedeon PLC
• Allergan PLC
• Neurocrine Biosciences Inc.
• BlackThorn Therapeutics Inc.
• Intra-Cellular Therapies Inc.
• Axsome Therapeutics Inc.
• Luye Pharma Group
• BioLite Inc.
• BrainsWay Ltd.
• Neumora Therapeutics Inc.
• Chase Therapeutics Corporation
• SAGE Therapeutics Inc.
• Arrivo Bioventures LLC
• Relmada Therapeutics Inc.
• Fabre-Kramer Pharmaceuticals Inc.
• Vistagen Therapeutics Inc.
What Is The Most Dominant Region In The Major Depressive Disorder Market?
North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
